AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01152099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymph Drainage (MLD) and Compression Bandaging
Description: Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied.
Study NCT02389881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 Solution
Study NCT02389881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-058
Description: TAK-058 Solution
Study NCT02389881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching solution
Study NCT00577590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin is taken alone
Study NCT00577590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is taken alone
Study NCT00577590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitizone is taken with Metformin
Study NCT00577590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza is taken with Metformin
Study NCT03461926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (SB-related planning + daily text messages)
Description: Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
Study NCT03115385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
Study NCT03115385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
Study NCT00986778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
Study NCT00986778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
Study NCT00986778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
Study NCT00986778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
Study NCT00986778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
Study NCT01079923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single High Dose Cholecalciferol
Description: Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
Study NCT01079923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily Dose Cholecalciferol
Description: Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
Study NCT03888495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender Socialization Training workshop
Description: Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.
Study NCT03888495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy Training Intervention
Description: Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.
Study NCT03888495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Planning Counseling and Services
Description: Family planning counseling sessions and linkage to services.
Study NCT01486238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen® pegaptanib sodium
Description: Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert.
Study NCT00152256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 10 mg Tablet, oral Daily for 6 months
Study NCT00152256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 25mg Tablet, oral Daily for 6 months
Study NCT00152256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet, oral Daily for 6 months
Study NCT01568411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-1211
Description: Period 1
Study NCT01568411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-1211+ itraconazole
Description: Period 2
Study NCT00736281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Drops: Food Allergens (peptides)
Description: The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
Study NCT03419702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
Study NCT05288465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
Study NCT02817204 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
Study NCT04675281 — intervention group
Intervention type: OTHER
Intervention: 2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks
Description: All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
Study NCT02348047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamilton T1
Study NCT02348047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton T1
Study NCT02233725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Definity Perflutren Injectable Suspension
Description: a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
Study NCT01277146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-59R5
Description: IV infusion
Study NCT05957562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EA/TOF primary repair with Azygos vein preservation
Description: primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
Study NCT05957562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EA/TOF primary repair with Azygos vein sacrifice (disconnection)
Description: primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
Study NCT02942407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: oral anticoagulant
Study NCT02942407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: oral anticoagulant
Study NCT02061592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Study NCT02061592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Study NCT02325453 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgical procedure performed with a robotic system.
Study NCT02325453 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Surgical procedure performed with laparoscopic techniques.
Study NCT02325453 — intervention group
Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Traditional approach for gastric cancer.
Study NCT03324958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality Helmet
Description: The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
Study NCT03324958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Virtual Reality Helmet
Description: The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
Study NCT02981693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal sealer
Description: Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
Study NCT02981693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal sealer
Description: Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
Study NCT01536509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Treatment (TBT)
Description: Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
Study NCT01536509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only (EO)
Description: Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
Study NCT01290731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100-mg capsule once daily for 12 weeks
Study NCT01290731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (pegIFN alpha-2a)
Description: 180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
Study NCT01290731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
Study NCT03390192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-mode stimulation
Description: 1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
Study NCT03390192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single sham stimulation
Description: 1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
Study NCT00601107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol
Study NCT00601107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04935294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study NCT02868528 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: chromosome screening with NGS technology
Study NCT01941056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-CMV epitope modified vaccinia Ankara vaccine
Description: Given IM
Study NCT01941056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02181738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02181738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Specified dose on specified days
Study NCT02181738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Specified dose on specified days
Study NCT02181738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Specified dose on specified days
Study NCT02083211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mAb Nimotuzumab
Description: This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
Study NCT02083211 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
Study NCT05472298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management intervention
Description: lifestyle modification, goal setting, coaching and peer support, problem-solving
Study NCT02794779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
Study NCT02794779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
Study NCT01149538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline bitartrate
Description: Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
Study NCT01149538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for choline bitartrate
Description: Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
Study NCT00837447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement with NexGen CR knee prosthesis
Description: comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
Study NCT00837447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement(TKR) with Nexgen CR-flex
Description: TKR using Nexgen CR-flex implant
Study NCT00601237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV-related text messaging
Description: Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
Study NCT00601237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition-related text messaging
Description: Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.